| Document |
Document Title |
|
WO/2018/042460A1 |
The present invention discloses sulphur functionalized polyurea composite of Formula (I) and Formula (II) that provides an insoluble solid support for effective removal of metal residues from solvent streams and other reservoirs and to t...
|
|
WO/2018/028665A1 |
Provided is a method for preparing an intermediate of 6-arylaminopyridonecarboxamide compound as an MEK inhibitor, comprising preparing a compound of formula (III) as an intermediate of 6-arylaminopyridonecarboxamide compound using a com...
|
|
WO/2017/168419A1 |
Disclosed methyl styrene farmin compounds, and crosslinked polymeric backbones comprising same. Further disclosed microsized and nanosized polymeric particles comprising polyisothiouronium methylstyrene (PITMS) and/or poly(methyl styrene...
|
|
WO/2017/170826A1 |
The purpose of the invention is to provide a compound useful in the prevention or treatment of diabetes, obesity, and conditions related thereto. The present invention relates to an enhancing agent for glucagon-like peptide-1 receptor ac...
|
|
WO/2017/099237A1 |
A compound represented by formula (I) and having a property of modulating the activity of an androgen receptor, or a pharmaceutically acceptable salt of the compound. X represents S or O; Z represents (Ra)n-A-(CR13R14)0-1-(CR11R12)0-1-; ...
|
|
WO/2017/096430A1 |
The present invention relates to hydroxamic acid-based compounds, their intermediates, preparation and uses. The compounds are useful in imaging, particularly for the imaging of tumours and cancer, and especially for the imaging of prost...
|
|
WO/2017/047572A1 |
A heat-sensitive recording material obtained by forming a heat-sensitive recording layer, which contains a basic dye and a developer, on a supporting body. The developer is composed of at least one N-substituted amino acid derivative rep...
|
|
WO/2016/207726A1 |
The present description provides oligourea catalysts, a polar helical oligomeric strands, and methods for catalyzing reactions with polar helical oligomeric strands and oligourea catalysts. In particular, the invention relates to a polar...
|
|
WO/2016/193284A1 |
The present invention relates to compounds of formula (I) as defined herein, to processes for preparing them, to pesticidal, in particular insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising them and to method...
|
|
WO/2016/184561A1 |
Novel inhibitors of the enzyme autotaxin are described. The inhibitors contain one or two zinc-binding groups at the appropriate distance, Also described are uses thereof, such as for the inhibition of autotaxin activity and the treatmen...
|
|
WO/2016/128924A1 |
The present invention relates to a new chemical synthesis, intermediates and catalysts useful for the preparation of the neprilysin (NEP) inhibitor sacubitril. It further relates to new intermediate compounds and their use for said new c...
|
|
WO/2016/079327A1 |
The invention relates to hydrosoluble hydroxybisphosphonic derivatives of doxorubicin of formula (I) and the pharmaceutically acceptable salts thereof. The invention also relates to the use of said compounds as a drug, especially in the ...
|
|
WO/2016/062585A1 |
The present invention relates to a compound of formula (I) wherein: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are as defined herein; and wherein the compound of formula (I) is optionally present as an agrochemically acce...
|
|
WO/2016/040226A1 |
In its many embodiments, the present invention provides certain C-6 spirocarbocyclic iminothiadiazine compounds, including compounds Formula (I): or a tautomer thereof, and pharmaceutically acceptable salts of said compounds and said tau...
|
|
WO/2015/157242A1 |
Lysophosphatidic acid acyltransferase-beta (LPAAT-β) catalyzes the production of phosphatidic acid (PA) from lysophosphatidic acid (LPA). The lipid cofactor PA contributes to the activation of c-Raf, BRAF, mTOR and PKC-ζ. LPAAT-β expr...
|
|
WO/2015/136292A1 |
The invention relates to a DDX3X inhibitorfor use in the treatment of pneumovirus infection in a mammal, wherein the DDX3X inhibitor may be a compound of Formula (I) wherein y, Z, R1, X, L, Ra and Rb are as defined herein. The invention ...
|
|
WO/2015/090209A1 |
Provided in the present invention are a general formula I compound, the isomers, pharmaceutically-acceptable salt or solvate thereof, and application thereof to manufacturing medicine for preventing and/or treating drug-resistant tumours...
|
|
WO/2015/054960A1 |
Provided are a novel Lesinurad intermediate, providing a synthetic process more economical, more efficient, safer, more environmentally friendly, and suitable for large-scale industrial production for the preparation of Lesinurad. Also p...
|
|
WO/2015/030085A1 |
A photosensitive layer comprises: a phthalocyanine crystal in which a urea compound is contained. The urea compound has one or more urea moieties comprising: a carbonyl group, or a thiocarbonyl group, and two nitrogen atoms. Each of the ...
|
|
WO/2014/205251A3 |
The present invention provides curable compositions comprising non-tin metal accelerators that accelerate the condensation curing of moisture-curable silicones/non-silicones. In particular, the present invention provides an accelerator c...
|
|
WO/2014/158654A1 |
Compounds of formula (II): wherein A, R1, R2, R5 and R13 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well...
|
|
WO/2014/143561A1 |
Compounds of formula (I): where R1, R2, R3, R4a, R4b, R5, R6 and R7 are defined herein, or stereoisomers or pharmaceutically acceptable salts thereof, are described herein. Such compounds have activity as SHIP1 modulators, and thus may b...
|
|
WO/2014/118556A3 |
Sphingosine 1-phosphate (S1P) is involved in hyper-proliferative diseases, such as cancer and vascular remodeling in pulmonary arterial hypertension. Inhibitors of sphingosine kinase 1 and 2 (SK1 and SK2), which catalyze the synthesis of...
|
|
WO/2014/087431A1 |
The present invention disclose an improved one pot process for synthesis of acyl thioureas of formula (I), with yield greater than 80%, from aroyl chlorides of formula (I) wherein, R' is an aryl or a heteroarylene group substituted with ...
|
|
WO/2014/087431A8 |
The present invention disclose an improved one pot process for synthesis of acyl thioureas of formula (I), with yield greater than 80%, from aroyl chlorides of formula (I) wherein, R' is an aryl or a heteroarylene group substituted with ...
|
|
WO/2014/004311A1 |
Benzoylthiourea or benzoylthiourethane derivatives as cure accelerators in primers for two step adhesive systems are provided
|
|
WO/2013/117843A1 |
Cosmetic composition comprising a multifunctional compound, compound and cosmetic treatment method. The invention relates to a cosmetic composition comprising at least one compound of formula (I): (Z)x-(L)w-(A)y in which: -x and y are in...
|
|
WO/2013/111798A1 |
[Problem] To provide a novel serine racemase inhibitor having a satisfactory activity and satisfactory specificity. [Solution] A serine racemase inhibitor comprising at least one compound selected from a compound group consisting of comp...
|
|
WO/2012/164118A1 |
The invention relates to compounds containing at least one polyphenol group and sulphur or selenium and to the uses thereof as antioxidants and free radical scavengers. In addition, the invention relates to pharmaceutical, nutraceutical ...
|
|
WO/2012/161518A3 |
The present invention relates to a novel compound for activating RORα genes, and to salts thereof. More specifically, the present invention relates to a novel JC1 compound containing CGP52608, which is a thiazolidinedione, as a lead sub...
|
|
WO/2012/161518A2 |
The present invention relates to a novel compound for activating RORα genes, and to salts thereof. More specifically, the present invention relates to a novel JC1 compound containing CGP52608, which is a thiazolidinedione, as a lead sub...
|
|
WO/2012/117941A1 |
This electrode active material has general formula (I) or (II) in the constituent units thereof. In the formulas, X is C or Si; and Y1 and Y2, or Y3 and Y4 are mutually different substituent groups selected from S, O, Se, Te, NH, SR1'R2'...
|
|
WO/2012/105438A1 |
An electrode active material having a dithionic structure indicated in general formula. The dithionic structure has a linking group (Z) interposed between X=S groups (X: C or Si). The linking group (Z) is CH2, CF2, O, S, SO2, Se, or N-R'...
|
|
WO/2012/036520A2 |
The present invention relates to a novel antibiotically active compound and to an antibiotic composition comprising the compound, and more specifically relates to a compound that inhibits microorganism lipid synthesis and to a use for th...
|
|
WO/2012/036520A3 |
The present invention relates to a novel antibiotically active compound and to an antibiotic composition comprising the compound, and more specifically relates to a compound that inhibits microorganism lipid synthesis and to a use for th...
|
|
WO/2012/037394A1 |
The present invention provides compositions and methods for stabilization of fluorescent dyes. In particular, the present invention provides buffer systems comprising thiourea to protect against degradation of ozone-labile fluorescent dyes.
|
|
WO/2012/021991A1 |
Carbamimidothioic acid esters of formula (I) and 2-nitro-N-[4-(pyridin-4-ylamino)phenyl]-4-(quinolin-4-ylamin
o)benzamide are used for the treatment of influenza, and for the inhibition of a viral RNA-dependent RNA polymerase. Formulae (...
|
|
WO/2012/021991A8 |
Carbamimidothioic acid esters of formula (I) and 2-nitro-N-[4-(pyridin-4-ylamino)phenyl]-4-(quinolin-4-ylamin
o)benzamide are used for the treatment of influenza, and for the inhibition of a viral RNA-dependent RNA polymerase. Formulae (...
|
|
WO/2012/010644A1 |
Process for the synthesis of an isothiocyanate of general formula (I) SCN‑R1-R4-R2 in which R1 and R2 represent, independently of one another, an alkyl, aryl or alkylaryl group, R4 represents a carbonyl, sulphinyl or sulphonyl group or...
|
|
WO/2012/004549A1 |
A compound of formula I-0, and its pharmaceutically acceptable salt or salts and physiologically hydrolysable derivatives in free form or salt form: wherein Z1 is C1-C4 linear or branched alkyl or alkenyl; R4 is selected from unsubstitut...
|
|
WO/2011/159137A2 |
The present invention relates to a novel thiourea or urea derivative, a preparation method thereof, and a pharmaceutical composition for preventing or treating AIDS, containing the same as an active ingredient. According to the present i...
|
|
WO/2011/159137A3 |
The present invention relates to a novel thiourea or urea derivative, a preparation method thereof, and a pharmaceutical composition for preventing or treating AIDS, containing the same as an active ingredient. According to the present i...
|
|
WO/2011/152471A3 |
Provided is a rechargeable battery with a higher degree of safety. Specifically provided is a rechargeable battery constituted so as to prevent overcharging. The rechargeable battery is a battery which uses a positive electrode material ...
|
|
WO/2011/152471A2 |
Provided is a rechargeable battery with a higher degree of safety. Specifically provided is a rechargeable battery constituted so as to prevent overcharging. The rechargeable battery is a battery which uses a positive electrode material ...
|
|
WO/2011/140681A1 |
The present invention discloses compounds of formula (I), isomers, pharmaceutical salts or solvates thereof. The present invention also discloses a composition comprising the compounds of formula (I), isomers, pharmaceutical salts or sol...
|
|
WO/2011/140832A1 |
The present invention discloses a compound of general formula (I), or isomer, pharmaceutically acceptable salt and solvate thereof, as well as composition, medicinal use, and preparative method thereof. Said composition further comprises...
|
|
WO/2011/108690A1 |
The disclosed composition containing a compound represented by general formula (I) (refer to the Description for the definitions of the symbols used in the formula), or a salt thereof, has excellent CaSR agonist effects and provides phar...
|
|
WO/2011/108724A1 |
An object is to provide a CaSR agonist agent that has excellent CaSR agonist effects, and particularly, a pharmaceutical product that can prevent or remedy diabetes or obesity by the effect of CaSR activation. The aforementioned object i...
|
|
WO/2011/084106A1 |
Disclosed herein is a compound of structure (A): In this compound, X is either O or S, R1 is a rigid group, R2 is a hydrophilic group such that (A) is capable of self-assembly in water, and R3 is an organic group.
|
|
WO/2011/076784A3 |
The present invention relates to a compound of formula (I): Formula (I), wherein: - n is 0, 1 or 2; - A is in particular CH or N; - X is in particular CO, SO2, CS, and R1 is in particular H, - R2 is a group of formula NR3R4 or OR5, R3 an...
|
